Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025
Sweroside, the effective component of jianwei shoutai pills, alleviates recurrent pregnancy loss by activating cAMP signaling pathway in maternal-fetal interface.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeng Lihua, Huang Xian, Chen Tingting, Yu Zhaoji, Huang Chen, Xia Bo, Huang Xuge, Li Kaiwei, Li Jingwe, Luo Songping, Gao Jie
Аннотация
BACKGROUND: Recurrent pregnancy loss (RPL) is a common disease of reproductive dysfunction that severely impairs female health. Jianwei Shoutai Pills (JSP), a classical prescription of Chinese medicine, have been widely used in the treatment of RPL. However, the effective components and mechanisms of JSP haven't been sufficiently illustrated.
PURPOSE: To explore the effective components and mechanisms of JSP in treating RPL.
METHODS: Effects of JSP on PRL were evaluated in CBA/J × DBA/2 mice model with pregnancy loss rates, morphology of placenta and embryos, as well as hormone levels. Then effective component was identified according to JSP components, plasma and placenta JSP-derived components analyzed by ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and Chinmedomics. Furthermore, the effects of the active component were evaluated using the CBA/J × DBA/2 mouse model. Its potential mechanism of action was predicted through network pharmacology and molecular docking, and subsequently validated by surface plasmon resonance (SPR) and western blot analysis.
RESULTS: JSP could well alleviate RPL in the CBA/J × DBA/2 mice model. Moreover, combining with JSP components, plasma and placenta JSP-derived components analysis, sweroside was the only overlapped component and considered as the effective component of JSP according to the good effects on RPL mice model. Network pharmacology identified 83 targets as the hub targets of sweroside in the treatment of RPL, and most genes were enriched in cAMP signaling pathway. SPR analysis indicated that sweroside is capable of binding to the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Subsequently, western blot results demonstrated a significant upregulation of proteins enriched in the cAMP signaling pathway following sweroside administration, suggesting the activation of this pathway.
CONCLUSION: Sweroside was identified for the first time as the active component of JSP capable of treating recurrent pregnancy loss (RPL) by activating the cAMP signaling pathway. This study provides novel insights into potential clinical therapies for RPL.
PURPOSE: To explore the effective components and mechanisms of JSP in treating RPL.
METHODS: Effects of JSP on PRL were evaluated in CBA/J × DBA/2 mice model with pregnancy loss rates, morphology of placenta and embryos, as well as hormone levels. Then effective component was identified according to JSP components, plasma and placenta JSP-derived components analyzed by ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and Chinmedomics. Furthermore, the effects of the active component were evaluated using the CBA/J × DBA/2 mouse model. Its potential mechanism of action was predicted through network pharmacology and molecular docking, and subsequently validated by surface plasmon resonance (SPR) and western blot analysis.
RESULTS: JSP could well alleviate RPL in the CBA/J × DBA/2 mice model. Moreover, combining with JSP components, plasma and placenta JSP-derived components analysis, sweroside was the only overlapped component and considered as the effective component of JSP according to the good effects on RPL mice model. Network pharmacology identified 83 targets as the hub targets of sweroside in the treatment of RPL, and most genes were enriched in cAMP signaling pathway. SPR analysis indicated that sweroside is capable of binding to the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Subsequently, western blot results demonstrated a significant upregulation of proteins enriched in the cAMP signaling pathway following sweroside administration, suggesting the activation of this pathway.
CONCLUSION: Sweroside was identified for the first time as the active component of JSP capable of treating recurrent pregnancy loss (RPL) by activating the cAMP signaling pathway. This study provides novel insights into potential clinical therapies for RPL.